GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

Summary

This is a proof of concept (POC) single arm study of GW640385, a protease inhibitor, in combination with RTV and 2 or more nucleoside reverse transcriptase inhibitors (NRTI) backbone. This study has a 48 week duration and is open to both treatment naive and experienced patients who are HIV positive. There are 3 intensive pharmacokinetic (PK) visits.

Timeline

Start

2004-10

Primary completion

2007-01

Completion

2007-01

Drugs

Indications